CU Medical Systems, Inc. (KOSDAQ:115480)
South Korea
· Delayed Price · Currency is KRW 2,740.00
+50.00 (1.86%)
At close: Apr 23, 2026
CU Medical Systems Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 819.2 | -3,204 | -8,204 | 9,425 | -13,981 | Upgrade
|
| Depreciation & Amortization | 3,293 | 2,658 | 1,935 | 1,651 | 1,945 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.5 | -8.7 | -119.88 | -861.77 | 10.49 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 1,055 | 2,781 | 370.57 | 5,267 | Upgrade
|
| Loss (Gain) From Sale of Investments | 8,585 | 9,214 | 9,637 | 1,024 | 8,046 | Upgrade
|
| Provision & Write-off of Bad Debts | 29.58 | -875.72 | 1,701 | -154.21 | -389.72 | Upgrade
|
| Other Operating Activities | 1,912 | 1,215 | 474.15 | 2,401 | 8,068 | Upgrade
|
| Change in Accounts Receivable | -3,820 | -641.81 | -2,005 | -4,348 | -2,165 | Upgrade
|
| Change in Inventory | -715.39 | 2,966 | 1,358 | -4,887 | -834.41 | Upgrade
|
| Change in Accounts Payable | -705.14 | -11.97 | 857.79 | 358.8 | 956.05 | Upgrade
|
| Change in Unearned Revenue | 147.4 | -11.5 | - | 64.26 | -524.64 | Upgrade
|
| Change in Other Net Operating Assets | 144.75 | 1,717 | -139.69 | -1,923 | -5,906 | Upgrade
|
| Operating Cash Flow | 9,687 | 14,072 | 8,275 | 3,121 | 490.43 | Upgrade
|
| Operating Cash Flow Growth | -31.16% | 70.06% | 165.11% | 536.46% | -94.17% | Upgrade
|
| Capital Expenditures | -1,058 | -20,056 | -6,382 | -11,586 | -5,186 | Upgrade
|
| Sale of Property, Plant & Equipment | 3.5 | 29.84 | 31.36 | - | 24.45 | Upgrade
|
| Cash Acquisitions | -440.23 | - | - | - | - | Upgrade
|
| Divestitures | - | - | 10 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -235.77 | -6.5 | -89.14 | -18.63 | 49.65 | Upgrade
|
| Investment in Securities | 4,378 | -11,577 | -4,783 | -5,652 | 2,735 | Upgrade
|
| Other Investing Activities | -3,131 | -260.16 | -308.62 | 2,737 | 231.97 | Upgrade
|
| Investing Cash Flow | -537.62 | -31,870 | -11,476 | -13,969 | -1,518 | Upgrade
|
| Short-Term Debt Issued | - | 2,050 | 1,000 | 8.18 | 11,102 | Upgrade
|
| Long-Term Debt Issued | - | 30,000 | 6,694 | 10,620 | 5,480 | Upgrade
|
| Total Debt Issued | - | 32,050 | 7,694 | 10,628 | 16,582 | Upgrade
|
| Short-Term Debt Repaid | -2,346 | -1,000 | - | -1,221 | -14,130 | Upgrade
|
| Long-Term Debt Repaid | -1,873 | -18,628 | -656.28 | -4,480 | -11,222 | Upgrade
|
| Total Debt Repaid | -4,219 | -19,628 | -656.28 | -5,701 | -25,352 | Upgrade
|
| Net Debt Issued (Repaid) | -4,219 | 12,422 | 7,037 | 4,927 | -8,770 | Upgrade
|
| Issuance of Common Stock | - | 8,009 | - | 373.3 | 19,009 | Upgrade
|
| Repurchase of Common Stock | - | -71.24 | - | - | - | Upgrade
|
| Other Financing Activities | - | 724.37 | -0 | - | - | Upgrade
|
| Financing Cash Flow | -4,219 | 21,085 | 7,037 | 5,300 | 10,239 | Upgrade
|
| Foreign Exchange Rate Adjustments | 103.25 | 363.21 | -70.4 | -191.36 | -12.01 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | -365.2 | Upgrade
|
| Net Cash Flow | 5,034 | 3,650 | 3,766 | -5,739 | 8,834 | Upgrade
|
| Free Cash Flow | 8,629 | -5,984 | 1,893 | -8,465 | -4,696 | Upgrade
|
| Free Cash Flow Margin | 17.89% | -14.73% | 4.53% | -18.03% | -13.26% | Upgrade
|
| Free Cash Flow Per Share | 737.35 | -588.26 | 197.93 | -937.51 | -692.09 | Upgrade
|
| Cash Interest Paid | 1,413 | 1,078 | 288.48 | 329.48 | 637.64 | Upgrade
|
| Cash Income Tax Paid | 469.48 | 277.37 | 1,377 | 347.03 | 398.71 | Upgrade
|
| Levered Free Cash Flow | 5,352 | -9,027 | -4,944 | 11,830 | 686.73 | Upgrade
|
| Unlevered Free Cash Flow | 6,255 | -8,310 | -4,741 | 12,114 | 1,397 | Upgrade
|
| Change in Working Capital | -4,948 | 4,018 | 70.62 | -10,734 | -8,474 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.